Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 10/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.40 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778181 | 0.86 | GPR132 (0.45) | GPR132FOLH1KMT2AHSD17B10CMKLR2 | |
| SCHEMBL7835941 | 0.86 | GPR132 (0.43) | GPR132FOLH1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6777425 | 0.84 | SUCNR1 (0.45) | — | |
| SCHEMBL6774904 | 0.83 | GPR132 (0.47) | GPR132FOLH1CMKLR2CMKLR1 | |
| SCHEMBL7838871 | 0.79 | ALDH1A1 (0.40) | LMNAKMT2APOLB | |
| SCHEMBL7341395 | 0.77 | MEN1 (0.42) | GPR132KMT2AHSD17B10CMKLR2CMKLR1 | |
| SCHEMBL7835830 | 0.77 | ITGB3 (0.47) | KMT2A | |
| SCHEMBL7336958 | 0.76 | KMT2A (0.42) | LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL6778020 | 0.76 | ITGB3 (0.48) | KMT2A | |
| SCHEMBL7838870 | 0.75 | ITGB3 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |